Inhibition of the notch-hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7324-7336

  Belyea, Brian C ^a   Naini, Sarasija ^a   Bentley, Rex C ^a   Linardic, Corinne M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR X; GAMMA SECRETASE INHIBITOR XII; INTRACELLULAR NOTCH1 RECEPTOR; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HEY 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYONAL RHABDOMYOSARCOMA; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARBAMATES; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIPEPTIDES; HUMANS; MICE; MICE, SCID; MUSCLE DEVELOPMENT; MUSCLES; RECEPTORS, NOTCH; RHABDOMYOSARCOMA, EMBRYONAL; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82555173147     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1004     Document Type: Article

References (44)

1. Huh WW, Skapek SX. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010;12:402-10.
2. Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist 1999;4:34-44. (Pubitemid 29102453)
3. Zweidler-McKay PA. Notch signaling in pediatric malignancies. Curr Oncol Rep 2008;10:459-68.
4. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res 2008;68:4727-35.
5. Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros JM, et al. A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med 2009;13:136-46.
6. Buas MF, Kadesch T. Regulation of skeletal myogenesis by Notch. Exp Cell Res 2010;316:3028-33.
7. Kitzmann M, Bonnieu A, Duret C, Vernus B, Barro M, Laoudj-Chenivesse D, et al. Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. J Cell Physiol 2006;208:538-48. (Pubitemid 44141878)
8. Shih I-M, Wang T-L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82. (Pubitemid 46424200)
9. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008;111:2220-9. (Pubitemid 351451536)
10. Engin F, Bertin T, Ma O, Jiang MM, Wang L, Sutton RE, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009;18:1464-70.
11. Sang L, Coller HA, Roberts JM. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 2008;321:1095-100.
12. Roma J, Masia A, Reventos J, Sanchez de Toledo J, Gallego S. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 2011;17:505-13.
13. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011;56:239-49.
14. Ancrile B, Lim K-H, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21:1714-9. (Pubitemid 47076470)
15. Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res 2007;67:6691-9. (Pubitemid 47105515)
16. Patel NS, Li J-L, Generali D, Poulsom R, Cranston DW, Harris AL. Upregulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005;65:8690-7. (Pubitemid 41377356)
17. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008;68:9583-8.
18. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010;28:1240-6.
19. Baldi A, De Falco M, De Luca L, Cottone G, Paggi MG, Nickoloff BJ, et al. Characterization of tissue specific expression of Notch-1 in human tissues. Biol Cell 2004;96:303-11. (Pubitemid 38618758)
20. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009;100:1957-65.
21. Kawamata S, Du C, Li K, Lavau C. Notch1 perturbation of hemopoiesis involves non-cell- autonomous modifications. J Immunol 2002;168:1738-45. (Pubitemid 34135772)
22. Sang L, Roberts JM, Coller HA. Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 2010;16:17-26.
23. Zhang P, Yang Y, Nolo R, Zweidler-McKay PA, Hughes DPM. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010;29:2916-26.
24. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008;14:2962-9.
25. Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helins K, et al. Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study. Tumori 2010;96:97-102.
26. Mullendore ME, Koorstra J-B, Li Y-M, Offerhaus GJ, Fan X, Henderson CM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009;15:2291-301.
27. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5:483-93.
28. Woo S-M, Kim J, Han H-W, Chae J-I, Son M-Y, Cho S, et al. Notch signaling is required for maintaining stem-cell features of neuroprogenitor cells derived from human embryonic stem cells. BMC Neurosci 2009;10:97.
29. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li Y-M, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-52. (Pubitemid 44289197)
30. Buas MF, Kabak S, Kadesch T. Inhibition of myogenesis by Notch: evidence for multiple pathways. J Cell Physiol 2009;218:84-93.
31. Buas MF, Kabak S, Kadesch T. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis. J Biol Chem 2010;285:1249-58.
32. Luo D, Renault VM, Rando TA. The regulation of Notch signaling in muscle stem cell activation and postnatal myogenesis. Semin Cell Dev Biol 2005;16:612-22. (Pubitemid 41247884)
33. Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008;2:50-9.
34. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-86. (Pubitemid 35033702)
35. Martinelli S, McDowell HP, Vigne SD, Kokai G, Uccini S, Tartaglia M, et al. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer 2009;48:975-82.
36. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007;21:1382-95. (Pubitemid 46871041)
37. Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, Kikuchi A, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006;45:583-91. (Pubitemid 43727165)
38. Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Res 2005;65:4490-5. (Pubitemid 40740781)
39. Tiffin N, Williams RD, Shipley J, Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer 2003;89:327-32. (Pubitemid 36976324)
40. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004;82:341-58. (Pubitemid 39485346)
41. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435: 959-63. (Pubitemid 40896322)
42. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009;15:50-8.
43. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid resistance in T cell acute lymphoblastic leukemia. Leukemia 2009;23:1374-7.
44. Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, et al. Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood 2008;111:705-14.